Doctors test 'Adaptive' chemo that adjusts dose based on tumor response
NCT ID NCT06525766
Summary
This study is testing a flexible approach to chemotherapy for advanced breast cancer that has spread. Researchers want to see if adjusting the dose of the drug capecitabine based on how the tumor responds—using scans and blood tests—can help control the cancer longer while possibly reducing side effects. The trial is for adults with estrogen receptor-positive, HER2-negative metastatic breast cancer who haven't had chemotherapy for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.